| 4213- | Hup, | Huperzine A-Liposomes Efficiently Improve Neural Injury in the Hippocampus of Mice with Chronic Intermittent Hypoxia |
| - | in-vivo, | NA, | NA |
| 4209- | Hup, | Huperzine A, reduces brain iron overload and alleviates cognitive deficit in mice exposed to chronic intermittent hypoxia |
| - | in-vivo, | NA, | NA |
| 4210- | Hup, | A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies–Emphasis on Alzheimer’s Disease Pathogenesis |
| - | Review, | AD, | NA |
| 4211- | Hup, | Huperzine A ameliorates obesity-related cognitive performance impairments involving neuronal insulin signaling pathway in mice |
| - | in-vitro, | NA, | NA |
| 7480- | Hup, | Pharmacokinetics of huperzine A following oral administration to human volunteers |
| - | Trial, | AD, | NA |
| 7479- | Hup, | A phase II trial of huperzine A in mild to moderate Alzheimer disease |
| - | Trial, | AD, | NA |
| 3805- | Hup, | Isolation, diversity and acetylcholinesterase inhibitory activity of the culturable endophytic fungi harboured in Huperzia serrata from Jinggang Mountain, China |
| - | Analysis, | AD, | NA |
| 3804- | Hup, | Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials |
| - | Review, | AD, | NA |
| 3803- | Hup, | Huperzine A and Its Neuroprotective Molecular Signaling in Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 3802- | Hup, | New insights into huperzine A for the treatment of Alzheimer's disease |
| - | Review, | AD, | NA |
| 3801- | Hup, | An update on huperzine A as a treatment for Alzheimer's disease |
| - | Review, | AD, | NA |
| 3800- | Hup, | Role of huperzine a in the treatment of Alzheimer's disease |
| - | Review, | AD, | NA |
| 3799- | Hup, | The use of Huperzia species for the treatment of Alzheimer's disease |
| - | NA, | AD, | NA |
| 7570- | HYP, | Hyperoside suppresses BMP-7-dependent PI3K/AKT pathway in human hepatocellular carcinoma cells |
| - | in-vitro, | Liver, | HepG2 |
| 7569- | HYP, | Inhibitory effects of hyperoside on lung cancer by inducing apoptosis and suppressing inflammatory response via caspase-3 and NF-κB signaling pathway |
| - | vitro+vivo, | Lung, | A549 |
| 7557- | HYP, | Hyperoside protects the blood-brain barrier from neurotoxicity of amyloid beta 1-42 |
| - | in-vitro, | AD, | NA |
| 7568- | HYP, | PacT, | Administration with hyperoside sensitizes breast cancer cells to paclitaxel by blocking the TLR4 signaling |
| - | in-vitro, | BC, | MDA-MB-231 |
| 7567- | HYP, | Hyperoside: A review on its sources, biological activities, and molecular mechanisms |
| - | Review, | Var, | NA |
| 7566- | HYP, | Hyperoside improves learning and memory deficits by amyloid β1-42 in mice through regulating synaptic calcium-permeable AMPA receptors |
| - | in-vivo, | AD, | NA |
| 7565- | HYP, | Potential Implications of Hyperoside on Oxidative Stress-Induced Human Diseases: A Comprehensive Review |
| - | Review, | AD, | NA |
| 7564- | HYP, | Pharmacological activities and therapeutic potential of Hyperoside in the treatment of Alzheimer's and Parkinson's diseases: A systemic review |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 7562- | HYP, | doxoR, | Hyperoside Inhibits Doxorubicin-Induced Ferroptosis in Cardiomyocytes via the Nrf2/GPX4 Pathway |
| - | in-vivo, | Nor, | NA |
| 7563- | HYP, | Hyperoside alleviates macrophages and microglia-mediated neuroinflammation and oxidative stress through activating PI3K/AKT and Nrf2/HO-1 signaling pathway post spinal cord injury |
| - | vitro+vivo, | Nor, | NA |
| 7548- | HYP, | Mechanistic evaluation of hyperoside against non-small cell lung cancer: a combined approach of network pharmacology and in vitro experimental validation |
| - | in-vitro, | NSCLC, | A549 |
| 7547- | HYP, | Hyperoside suppresses NSCLC progression by inducing ATG13-mediated autophagy and apoptosis |
| - | vitro+vivo, | NSCLC, | NA |
| 7546- | HYP, | Hyperoside attenuates hydrogen peroxide-induced L02 cell damage via MAPK-dependent Keap₁-Nrf₂-ARE signaling pathway |
| - | in-vitro, | Nor, | L02 |
| 7549- | HYP, | Rad, | Study on the mechanism of hyperoside in affecting the biological progression and radiosensitivity of esophageal carcinoma by modulating the STAT3/AKT/ERK pathway |
| - | vitro+vivo, | ESCC, | TE1 | - | vitro+vivo, | ESCC, | KYSE150 |
| 7545- | HYP, | Hyperoside induces ferroptosis in chronic myeloid leukemia cells by targeting NRF2 |
| - | in-vitro, | CML, | K562 |
| 7550- | HYP, | Hyperoside Induces Breast Cancer Cells Apoptosis via ROS-Mediated NF-κB Signaling Pathway |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | 4T1 |
| 7551- | HYP, | Hyperoside exhibits anticancer activity in non‑small cell lung cancer cells with T790M mutations by upregulating FoxO1 via CCAT1 |
| - | vitro+vivo, | NSCLC, | NA |
| 7552- | HYP, | Hyperoside exerts potent anticancer activity in skin cancer |
| - | vitro+vivo, | Melanoma, | NA |
| 7554- | HYP, | Effect of hyperoside on the apoptosis of A549 human non‑small cell lung cancer cells and the underlying mechanism |
| - | in-vitro, | NSCLC, | A549 |
| 7555- | HYP, | RT, | Hyperoside and rutin of Nelumbo nucifera induce mitochondrial apoptosis through a caspase-dependent mechanism in HT-29 human colon cancer cells |
| - | in-vitro, | Colon, | HT29 |
| 7556- | HYP, | Hyperoside induces apoptosis and inhibits growth in pancreatic cancer via Bcl-2 family and NF-κB signaling pathway both in vitro and in vivo |
| - | vitro+vivo, | PC, | NA |
| 7558- | HYP, | The Cytoprotective Effect of Hyperoside against Oxidative Stress Is Mediated by the Nrf2-ARE Signaling Pathway through GSK-3β Inactivation |
| - | in-vivo, | AD, | NA |
| 7553- | HYP, | Hyperoside induces both autophagy and apoptosis in non-small cell lung cancer cells in vitro |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Nor, | BEAS-2B |
| 7561- | HYP, | Hyperoside Exerts Therapeutic Effects on Parkinson's Disease by Mitigating Oxidative Stress through Activation of Nrf2/HO-1 Pathway |
| - | in-vivo, | Park, | NA |
| 7560- | HYP, | Hyperoside: A Review of Its Structure, Synthesis, Pharmacology, Pharmacokinetics and Toxicity |
| - | Review, | Nor, | NA | - | Review, | AD, | NA |
| 7544- | HYP, | Long-term oral administration of hyperoside ameliorates AD-related neuropathology and improves cognitive impairment in APP/PS1 transgenic mice |
| - | in-vivo, | AD, | NA |
| 7596- | I3C, | Selective responsiveness of human breast cancer cells to indole-3-carbinol, a chemopreventive agent |
| - | in-vitro, | BC, | NA |
| 7600- | I3C, | Indole-3-Carbinol (I3C) and its Major Derivatives: Their Pharmacokinetics and Important Roles in Hepatic Protection |
| - | Review, | Nor, | NA |
| 7601- | I3C, | Prevention and treatment of cancer with indole-3-carbinol |
| - | Review, | BC, | NA |
| 7602- | I3C, | Dose-ranging study of indole-3-carbinol for breast cancer prevention |
| - | Trial, | BC, | NA |
| 7603- | I3C, | Modulation of CYP19 expression by cabbage juices and their active components: indole-3-carbinol and 3,3′-diindolylmethene in human breast epithelial cell lines |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF-10AT |
| 7604- | I3C, | Multifunctional aspects of the action of indole-3-carbinol as an antitumor agent |
| 7605- | I3C, | Indole-3-carbinol and prostate cancer |
| - | Review, | Pca, | NA |
| 7606- | I3C, | Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol |
| - | Human, | Nor, | NA |
| 7607- | I3C, | Indole-3-carbinol induces G1 cell cycle arrest and apoptosis through aryl hydrocarbon receptor in THP-1 monocytic cell line |
| - | in-vitro, | AML, | THP1 |
| 7608- | I3C, | Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells |
| - | in-vitro, | Pca, | PC3 |
| 7609- | I3C, | Molecular Targets, Anti-cancer Properties and Potency of Synthetic Indole-3-carbinol Derivatives |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid